<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373278">
  <stage>Registered</stage>
  <submitdate>24/07/2017</submitdate>
  <approvaldate>28/07/2017</approvaldate>
  <actrnumber>ACTRN12617001110370</actrnumber>
  <trial_identification>
    <studytitle>The short term effects of Gravity Relief Mobilisation massage therapy on chronic low back pain.</studytitle>
    <scientifictitle>Effects of Gravity Relief Mobilisation on Chronic Low Back Pain: a series of single-case experiments.</scientifictitle>
    <utrn>U1111-1199-0826 </utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Low Back Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Physical Medicine / Rehabilitation</conditioncode1>
      <conditioncode2>Other physical medicine / rehabilitation</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The intervention (phase 'B') involves attendance to a series of treatment sessions over 12 weeks and  no further treatments over a follow up sub-phase of 12 weeks. The follow up period cannot be considered a seperate withdrawal phase because potential carry over effects are not expected to return to base line levels immediately after ceasing treatments. 

The treatment sessions consist of a massage therapy based clinical intervention that a utilises a process approach to rehabilitation (Lederman, 2015). The intervention is comprised of both manual therapy and educational components that address the musculoskeletal system. The main activity is a novel form of myofascial release type indirect manual therapy that we have called Gravity Relief mobilisation (GRM). 

GRM induces muscle contraction and relaxation to gently mobilise tissues and joints. This is achieved indirectly by the amelioration of gravity, activating the mobilisation of nerves, muscles, connective tissues, and joints. The mechanism at work induces reflex like non-volitional motor activity. Coupled to the amelioration of gravity are holding techniques and angular cross stretches that are applied with the hands gently to the soft tissues . 

Preceding application of GRM, gliding and kneading massage techniques are used to induce a feel-good relaxation effect. During the treatment if appropriate breathing mechanics are discussed and practiced  at the time thoracic and cervical regions are being addressed. The treatment sessions will conclude with exercise and stretching advice and salient postural problems are attended to with education about good standing posture and how this may be achieved. In addition, movement education of basic movements is incorporated, if indicated by pain or difficulty with daily activities. Follow up advice to practice the exercises at home is given to consolidate treatment session gains. 

The interventions manual therapy components are applied with the participant lying comfortably on a massage table, they may be undressed down to their underwear for massage contact with the skin. The table is adjusted for tilt and bolsters are used for maximal comfort. 

Participants will be draped at all times with only the body region being worked on exposed, buttocks and chest areas will remain covered at all times. The participant may choose to receive the treatment fully dressed wearing light flexible clothing. Participant comfort and sense of security is prioritised.

The intervention consists of a minimum of four and maximum of 12 treatment sessions delivered over the course of 12 weeks.  The treatment sessions will be booked a maximum of three weeks apart and a minimum of one week apart. This will be negotiated between the participant and the therapists recommendations, reflecting clinical practice procedures.

An increase in pain lasting for 24-72 hours, is sometimes observed after a treatment session,  therefore follow ups are scheduled according to the response and recovery from previous treatments. This ensures that any adverse effects will not interfere with important roles and responsibilities of the participant.

Each treatment session is between 1 - 1 1/2 hours duration. The length of the session is influenced by client tolerance for lying on the table. Treatment times for participants who have allodynia or experience distress in static positions will be titrated. Sessions will start at no longer than 60 minutes including assessment. If the response and recovery is acceptable to the client the next session time will be increased by 15 minutes until the 90 minute maximum is reached.

The intervention has been developed and will be delivered by a qualified and Massage New Zealand (MNZ) Level 7 registered massage therapist with 12 years clinical practice experience. 

All treatment sessions are being video recorded and a random selection viewed for the purpose of assessing fidelity. Observer XT software will be used to code the practitioners observable behaviours, and the resulting data assessed against a list of required behaviours. The required behaviours correspond to a detailed treatment manual and are bound by minimum and maximum durations.

Intervention fidelity is being assessed by another MNZ Level 7 registered massage therapist who holds a Masters Degree in Health Science and works as a research fellow. This therapist is the treatment manuals co-author and will be trained in the novel GRM technique before the participants cross over to the intervention phase. As the therapist conducting the fidelity assessment is already highly qualified in massage and rehabilitation studies, only GRM training is needed. 

Training will consist of demonstration of GRM techniques on a volunteer by the interventions developer, following the techniques as they are outlined in "Chronic Low Back Pain Treatment manual V1.0 Characterisation of a Novel Intervention"(Verhagen and Brown, 2017). 

The treatment manual describes in detail how GRM is applied to each of the body regions. The regions are specified as: head (cephalic), neck (cervical), back (dorsal- below neck to below waist not including shoulders), ribs or thoracic (trunk), pelvis, shoulders-arms-hands (upper extremity), hips-knees-feet and ankles (lower extremity). The abdomen is not targeted in this intervention. 

The GRM training will consist of an hour demonstration and an hour of practice.</interventions>
    <comparator>Each single case-experiment has a control phase 'A', to establish the baseline level and stability of participants low back pain with repeated measurements.

Each control (phase 'A'), consists of randomised baseline length of 3,4,5,6 or 7 weeks. During baseline measurement the participant will be required to complete an online pain assessment survey called the PainQuILT 3x/week on specified days and at a time chosen by them. They will log onto the survey tool with an anonymised email address allocated to them which is password protected. The PainQuILT takes approximately 5 minutes to complete. 

At time of enrolment participants will be trained how to use the PainQuILT tool following the PainQuILT Demonstration Guide provided by the tools licensors, Mc Masters University.
</comparator>
    <control>Active</control>
    <interventioncode>Rehabilitation</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A change in the PainQuILT survey mean pain intensity score.  

Possible adverse effects after treatment session delivery of increase in mean pain intensity is also being monitored with the PainQuILT survey.</outcome>
      <timepoint>Participant outcomes will be measured repeatedly by ecological momentary assessments (EMA).
 Phase 'A':
*3x per week for duration of the baseline period (3-7 weeks)
Phase 'B':
* 1x per week on a day specified by the participant. 
*immediately before and after treatment sessions and, 
*3 days consecutively after their treatment sessions.

Each EMA is to completed at the same time of day +/- 1 hour, If a day is missed it may be completed on the following day at the same time.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>A change in the PainQuILT survey number of painful sites.

Possible adverse effects after treatment session delivery of increase in number of painful sites is also being monitored with the PainQuILT survey.</outcome>
      <timepoint>Participant outcomes will be measured repeatedly by EMA.
 Phase 'A':
*3x per week for duration of the baseline period (3-7 weeks)
Phase 'B':
* 1x per week on a day specified by the participant. 
*immediately before and after treatment sessions and, 
*3 days consecutively after their treatment sessions.

Each EMA is to completed at the same time of day +/- 1 hour, If a day is missed it may be completed on the following day at the same time.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>A change in the PainQuILT survey pain interference score.

Possible adverse effects after treatment session delivery of increase pain interference score  is also being monitored with the PainQuILT survey.</outcome>
      <timepoint>Participant outcomes will be measured repeatedly by EMA.
 Phase 'A':
*3x per week for duration of the baseline period (3-7 weeks)
Phase 'B':
* 1x per week on a day specified by the participant. 
*immediately before and after treatment sessions and, 
*3 days consecutively after their treatment sessions.

Each EMA is to completed at the same time of day +/- 1 hour, If a day is missed it may be completed on the following day at the same time.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>A change in the PainQuILT survey mean pain intensity score.  </outcome>
      <timepoint>EMA during follow up sub-phase:
* 1x/week for 12 weeks, on a day specified by the participant .

Each EMA is to completed at the same time of day +/- 1 hour, If a day is missed it may be completed on the following day at the same time.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>A change in the PainQuILT survey number of painful sites.</outcome>
      <timepoint>EMA during follow up sub-phase:
* 1x/week for 12 weeks, on a day specified by the participant .

Each EMA is to completed at the same time of day +/- 1 hour, If a day is missed it may be completed on the following day at the same time.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>A change in the PainQuILT survey pain interference score.</outcome>
      <timepoint>EMA during follow up sub-phase:
* 1x/week for 12 weeks, on a day specified by the participant .

Each EMA is to completed at the same time of day +/- 1 hour, If a day is missed it may be completed on the following day at the same time.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PainQuILT User Acceptability e-scale</outcome>
      <timepoint>After the completion of the 12 week follow up sub-phase.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>*self-reported low back pain located on the posterior of the body from the inferior margin of the 12th rib to the gluteal folds
*low back pain for 6 months or longer and
*low back pain experienced at least half of the days of the past 6 months 
*non-responsive to usual care (as per ACC Acute Low Back Pain Guide) and over-the-counter pain relief. 






</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>*receiving treatment for low back pain (other than over-the-counter pain relief)
*underlying medical condition contraindicating massage therapy
*body mass index (Weight/HeightÂ²) greater than 40kg/m2
*currently under care of a clinical psychologist or psychiatrist
*pregnancy or delivered birth in the last 12 months
*scheduled to begin a new treatment for pain relief either naturopathic or allopathic or other medical intervention within study period
*substance abuse and addictions
*unable to use an electronic device with internet or mobile access
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>This study contains five across-subject replications of a single-case experiment using a bi-phasic A-B design. Phase A is the control phase and phase B is the intervention phase. 

Phase B consists of a treatment period (12 weeks) and a follow-up sub-phase (12 weeks). The treatment period includes additional sub phases after treatment sessions (3 consecutive days). The phases are determined a priori.

An intermediary person will screen potential participants for eligibility and participants are blinded to baseline length until after completing the enrollment process. 

Each participant will be allocated a random baseline length between 3-7 weeks duration. The baseline allocation schedule is being held off site consisting of a simple sequence of computer generated random whole numbers. 
</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Statistical analysis: for each individual subject, each outcome variable (mean pain intensity, number of painful sites and pain interference score) will be assessed longitudinally using visual analysis, SCED specific d-statistic comparing the mean of baseline measures with the mean of the treatment phase measures (Hedges, Pustejovsky, &amp; Shadish, 2012), mean phase difference (MPD) and slope and level change (SLC) using the R code provided by Manolov and meta-analysis of the MPD and SLC. The MPD and SLC allow for an analysis of data adjusting for unstable baseline trends. The SCED specific d-statistic incorporates between-individual differences as well as within-individual differences. The meta-analysis of MPD and SLC provides a convenient way of summarising the data across all studied subjects.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>31/07/2017</anticipatedstartdate>
    <actualstartdate>4/08/2017</actualstartdate>
    <anticipatedenddate>4/09/2017</anticipatedenddate>
    <actualenddate>5/09/2017</actualenddate>
    <samplesize>5</samplesize>
    <actualsamplesize>5</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Bay of Plenty</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>Department of Medicine,
University of Otago Wellington,
23a Mein St,
Newtown,
Wellington 6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Otago</fundingname>
      <fundingaddress>362 Leith St,
North Dunedin,
Dunedin 9016.</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Heidi H Verhagen</fundingname>
      <fundingaddress>T/A Forte Body Reconditioning
Po Box 12 037,
Rotorua South,
Rotorua 3045.</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Melanie Brown</othercollaboratorname>
      <othercollaboratoraddress>Rehabilitation Teaching and Research Unit
University of Otago Wellington
23a Mein St,
Newtown,
Wellington 6021.</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The intervention under study comprises of established manual therapy techniques and a novel in-direct technique being called Gravity Relief Mobilisation (GRM). Observations in clinical practice have suggested that GRM may be an effective intervention for chronic musculoskeletal pain however some transitory adverse effects have been noted. This study will investigate the short term effects of GRM on pain and pain interference with functioning of people with chronic low back pain. Respectively the primary and secondary hypotheses are that the intervention will cause an  increase in pain up to three days after each treatment session and a stable reduction in pain and improvement in functional outcomes in the short term of three months. Outcomes will be measured using an online and mobile application.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Otago Human Ethics Committee (Health)</ethicname>
      <ethicaddress>362 Leith St, 
North Dunedin, 
Dunedin 9016.</ethicaddress>
      <ethicapprovaldate>21/07/2017</ethicapprovaldate>
      <hrec>H17/063</hrec>
      <ethicsubmitdate>14/07/2017</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Rebecca Grainger</name>
      <address>Department of Medicine,
University of Otago Wellington,
23a Mein St,
Newtown,
Wellington 6021.</address>
      <phone>+64 4 806 1031</phone>
      <fax />
      <email>Rebecca.grainger@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Heidi Verhagen</name>
      <address>T/A Forte Body Reconditioning,
PO Box 12037,
Rotorua South,
Rotorua 3045.</address>
      <phone>+64 7 350 3373</phone>
      <fax />
      <email>heidie@fortebody.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Heidi Verhagen</name>
      <address>T/A Forte Body Reconditioning,
PO Box 12037,
Rotorua South,
Rotorua 3045.</address>
      <phone>+6473503373</phone>
      <fax />
      <email>heidie@fortebody.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Heidi Verhagen</name>
      <address>T/A Forte Body Reconditioning
PO Box 12 037,
Rotorua South,
Rotorua 3045.</address>
      <phone>+64 7 350 3373</phone>
      <fax />
      <email>heidie@fortebody.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>